OBJECTIVE: To analyse the compliance of patients and side effects of Implanon® during breast feeding. MATERIAL AND METHODS: Prospective study of 61 postpartum women who chose Implanon® for long term contraception between April 2007 and December 2009. Compliance, side effects and removals were recorded. RESULTS: Amenorrhoea, prolonged bleeding, frequent bleeding and infrequent bleeding were reported in 20 (32%), 13 (21%), 4 (6.5%) and 2 (3.2%) patients, respectively. Non-menstrual side effects experienced by participants included; weight gain reported by 10 patients (16%), anxiety by 6 (9.8%), breast tenderness by 4 (6.5%), headache by 4 (6.5%), pain at the insertion site by two (3.2%), hirstutism by two (3.2%), acne by 1 (1.6%), loss of libido by 1 (1.6%), weight gain and headache by two (3.2%), weight gain and anxiety by two (1.6%). The mean breastfeeding period was 16±7.4/months. During the follow up, Implanon® was removed from 24 patients (39%). CONCLUSION: If patients are well informed about its expected side effects before placement, Implanon® is well tolerated and i an acceptable choice for women who have recently experienced labor and are looking for long term reversible contraception.
OBJECTIVE: To analyse the compliance of patients and side effects of Implanon® during breast feeding. MATERIAL AND METHODS: Prospective study of 61 postpartum women who chose Implanon® for long term contraception between April 2007 and December 2009. Compliance, side effects and removals were recorded. RESULTS: Amenorrhoea, prolonged bleeding, frequent bleeding and infrequent bleeding were reported in 20 (32%), 13 (21%), 4 (6.5%) and 2 (3.2%) patients, respectively. Non-menstrual side effects experienced by participants included; weight gain reported by 10 patients (16%), anxiety by 6 (9.8%), breast tenderness by 4 (6.5%), headache by 4 (6.5%), pain at the insertion site by two (3.2%), hirstutism by two (3.2%), acne by 1 (1.6%), loss of libido by 1 (1.6%), weight gain and headache by two (3.2%), weight gain and anxiety by two (1.6%). The mean breastfeeding period was 16±7.4/months. During the follow up, Implanon® was removed from 24 patients (39%). CONCLUSION: If patients are well informed about its expected side effects before placement, Implanon® is well tolerated and i an acceptable choice for women who have recently experienced labor and are looking for long term reversible contraception.
Entities:
Keywords:
Implanon; breastfeeding; compliance; etonogestrel; postpartum contraception; removal; side effect
Authors: Emily A DeFranco; David M Stamilio; Sarah E Boslaugh; Gilad A Gross; Louis J Muglia Journal: Am J Obstet Gynecol Date: 2007-09 Impact factor: 8.661
Authors: Paul D Blumenthal; Kristina Gemzell-Danielsson; Maya Marintcheva-Petrova Journal: Eur J Contracept Reprod Health Care Date: 2008-06 Impact factor: 1.848
Authors: Igor Fernando de Aquino Moreira; Maria Passos Bianchini; Gabrielle Rodrigues Campos Moreira; Alessandra Maciel Almeida; Bruno Almeida Rezende Journal: BMC Womens Health Date: 2020-10-27 Impact factor: 2.809